UPDATE: JPMorgan Downgrades Healthcare Trust of America (HTA) to Neutral
- Wall Street closes rollercoaster week sharply lower
- Invesco (IVZ) Reportedly in Talks to Merge With State Street's (STT) Asset Management Business, Citi Sees More Cons than Pros
- FDA Votes "No" on Pfizer (PFE) Booster for 16+ Age Group, 2 Yes 16 No
- Jefferies Raises Price Targets on Alphabet (GOOGL) and Facebook (FB) as They Are Still Inexpensive Relative to Growth, Reiterates Snap (SNAP) as a Best Growth Idea
- Tesla (TSLA) Could Deliver 900K EV Units This Year and 1.3M in 2022 - Wedbush
JPMorgan analyst Michael W. Mueller downgraded Healthcare Trust of America (NYSE: HTA) from Overweight to Neutral with a price target of $29.00.
The analyst comments "We are moving our rating on HTA from Overweight to Neutral. We view today’s action as simply resetting some of our ratings (in our relative rating system) to reflect a more favorable view of some stocks that have been disproportionately impacted by COVID-19 headwinds. As it relates to HTA’s business, we continue to anticipate stable core growth over the near-to-intermediate term, supplemented by acquisitions and some development. For income-oriented investors, the stock offers a dividend yield that is ~125 bps higher than that of the overall REIT group."
Shares of Healthcare Trust of America closed at $27.34 yesterday.
You May Also Be Interested In
- Las Vegas Sands (LVS) Downgraded to Hold at Jefferies on Limited Upside Potential
- Rio Tinto Plc. (RIO:LN) (RIO) PT Lowered to GBP54.10 at Morgan Stanley
- Innergex Renewable Energy (INE:CN) (INGXF) PT Raised to Cdn$28 at National Bank Financial
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!